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  ABSTRACT 
 
PROFILING FLAVONOID CYTOTOXICITY IN HUMAN  
BREAST CANCER CELL LINES 
 
by 
Sina Yadegarynia 
 
Flavonoids are part of a large family of polyphenols that are found 
extensively in fruits and vegetables.  This class of compounds has been of 
considerable medical interest due to their anti-inflammatory and anti-cancer 
activities.  Although extensive effort has been made to identify the biological 
effects responsible for the chemopreventive activity of these compounds, the 
exact molecular mechanisms involved are not fully understood.  In this study, we 
focused on the cytotoxic effects of fourteen different flavonoids against a series 
of breast cancer cell lines and evaluated the induction of cell cycle arrest at G1 or 
G2/M phase as result of such treatment.  We also assessed a possible structure-
function relationship for cellular cytotoxicity based on the various chemical 
structures of flavonoids.  The results showed that several flavonoids were 
cytotoxic in all cell lines even in the absence of certain signaling pathways.  In 
addition, only some flavonoids were able to induce cell cycle arrest, suggesting 
their cytotoxic potential may be independent of their ability to block cells at G1 or 
G2/M phases.  Our results enabled identification of certain structural properties 
that are important for the anticancer activity of flavonoids.  Finally, these results 
suggested that cytotoxicity does not depend on a particular signaling pathway. 
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INTRODUCTION 
 Cancer has been thought to be a preventable disease due to its slow 
development and progression, taking many years to become invasive in a step-
by-step manner [1].  Such property provides a great opportunity not only for early 
detection, but also for prevention of the disease progression.  Despite this, breast 
cancer is the most frequently diagnosed cancer in women worldwide and ranks 
second as a cause of cancer death [2].  It has been estimated that more than 
two-thirds of human cancers could be prevented through lifestyle modifications, 
such as dietary habits [3].  As early as 1676, when Dr. Wiseman proposed that 
cancer might arise from “an error in diet,” diet has been considered an important 
factor in cancer development [4].  
 Over the past several decades, there has been a particular interest in the 
role of flavonoids in cancer prevention.  Flavonoids are naturally occurring 
polyphenols widely distributed in fruits, vegetables, and beverages including teas 
and wine [4].  They represent a large portion of the compounds found in plants 
with more than 5,000 varieties [5].  Flavonoids are reported to have a range of 
biological activities including anti-oxidant, anti-inflammatory, and anti-tumorigenic 
properties.  In particular, flavonoids are active at different stages of cancer 
development by protecting DNA from oxidative damage, activating carcinogen 
metabolism and detoxification, preventing cellular proliferation, and/or inducing 
cellular cytotoxicity [6-10].  
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 A survey of the literature shows a plethora of effects of flavonoids on tumor 
and normal cell types, but the exact molecular mechanisms of flavonoid action 
are not fully understood.  Consequently, a careful characterization is needed to 
establish a reference point for further analysis of flavonoids and potential 
derivatives, which may provide a novel mechanism targeting clinical treatment 
and prevention of cancer.  
 
Table 1.  Some of the signaling components of the cell lines in this study.  
A (+) indicates present, (-) indicates absent, and (+/-) indicates weak expression.  
IDC: Invasive Ductal Carcinoma; AC: Adenocarcinoma; ESR1: estrogen 
receptor-1; PR: progesterone receptor; HER2: human epidermal growth factor 
receptor-2. 
Cell Line Tumor Type Invasiveness 
Gene 
Cluster 
Subtype 
p53 ESR1 PR HER2 
BT-474 IDC Strong Luminal Temperature sensitive (E285K) + + ++ 
MCF-7 IDC Weak Luminal Wild type + + + 
MDA-MB-231 AC Strong Basal Nonfunctional (R280K) - - - 
SK-BR-3 AC Strong Luminal Missense (R175H) - - ++ 
ZR-75-1 IDC Moderate Luminal Wild type +/- + +/- 
 
 
We, therefore, conducted a study to characterize the effects of fourteen 
flavonoids on a variety of human breast cancer cell lines (Table 1 and 2).  It has 
been determined that these commercially available breast cancer cell lines mirror 
the genomic, transcriptional, and biological heterogeneity of the primary tumors 
[11].  These cell lines were selected based upon the presence of mutations 
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Table 2.  Sub-classes and chemical structures of flavonoids in this study.  
OMe indicates methylated analogues, methylapigenin: 5,7,4’-trimethoxyflavone.	  
Substitution 
Subclasses and Structures Name 
5 6 7 8 2’ 3’ 4’ 5’ 
Apigenin OH H OH H H H OH H 
Methylapigenin OMe H OMe H H H OMe H 
Chrysin OH H OH H H H H H 
Luteolin OH H OH H H OH OH H 
Flavones 
 
Methylluteolin OMe H OMe H H OMe OMe H 
Kaempherol OH H OH H H H OH H 
Myricetin OH H OH H H OH OH OH 
Quercetin OH H OH H H OH OH H 
Flavonols 
 
Methylquercetin OMe H OMe H H OMe OMe H 
Naringenin OH H OH H H H OH H Flavanones 
 
Methylnaringenin OMe H OMe H H H OMe H 
Flavanol 
 
(+)-Catechin OH H OH H H OH OH H 
Daidzein H H OH H H H OH H Isoflavones 
 
Genistein OH H OH H H H OH H 
Modified from Yadegarynia et al. [12]
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in various signaling pathways.  Mutations are reported in estrogen receptor-1 
(ESR1), human epidermal growth factor-2 (HER2/ERBB2), progesterone 
receptor, and tumor suppressor protein (p53).  These cell lines have been used 
in many studies to individually investigate the role of each flavonoid (Table 3).  
For comparison with a non-transformed cell type, we used normal human 
mammary epithelial cells (HMEC) with a lifespan of only 15 to 20 passages in 
culture.  HMECs are not immortalized, unlike MCF10A which have been 
previously used in studies [13].  Such information may be used to help elucidate 
the specific signaling pathways utilized by flavonoids for the induction of cellular    
cytotoxicity. 
 
Table 3.  A survey of literature for effects of the flavonoids on breast cancer 
cell line proliferation and cytotoxicity. 
Cell Line Flavonoid Used Reference 
BT-474 Apigenin, Genistein [14, 15] 
MCF-7 Apigenin, Catechin, Genistein, Kaempherol, Myricetin, Naringenin, Quercetin [16-24] 
MDA-MB-231 Apigenin, Genistein, Kaempherol, Naringenin, Quercetin [6, 17, 25-37] 
SK-BR-3 Apigenin, Genistein, Quercetin [38-40] 
ZR-75-1 Apigenin, Genistein, Kaempherol, Quercetin [41-45] 
MCF10A/HMEC Apigenin, Daidzein, Genistein, Quercetin, Naringenin [13, 24, 46-49] 
 
 
In this study, we showed that some flavonoids induced cell death in all cell 
lines tested, including HMECs. Furthermore, we suggest that flavonoids might 
5 
induce cellular cytotoxicity through a generalized, signaling pathway-
independent, mechanism. 
6 
LITERATURE REVIEW 
Chemistry of Flavonoids 
Plants are rich sources of chemically diverse compounds, many with 
beneficial properties to human health.  Consequently, about 50% of the 
anticancer therapeutic agents known are derived from plants [50].  For example, 
compounds such as Taxol and vinca alkaloids act to destabilize the microtubules 
of cancer cells, preventing the rapid proliferation of tumors [51].  Polyphenolic 
compounds make up one of the most abundant groups of compounds in the plant 
kingdom [9].  They are secondary metabolites involved in many important 
functions in plants.  Some of these functions include UV protection, defense 
against biotic and abiotic stresses, pigmentation, and normal growth and 
development [52].  Polyphonels are divided into 10 general classes with more 
than 8,000 compounds identified to date.  The most abundant occurring 
polyphenols are flavonoids, accounting for about 60% of the polyphenols.  
Flavonoids are divided into six sub-classes based on their chemical structure, 
including flavanols, flavones, flavanones, flavonols, isoflavones, and 
anthocyanidins. 
The chemical structure of flavonoids is characterized by a 
diphenylpropane carbon skeleton of C6-C3-C6, where two benzene rings are 
linked by a 3-carbon chain forming a heterocyclic pyran or pyrone ring with an 
oxygen.  Differences in the number and arrangement of the hydroxyl groups lead 
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to variations within each group.  Flavonoids may be hydroxylated at positions 3, 
5, 7, 3’, 4’, and/or 5’ (Table 2).  Except for isoflavones, where the B-ring is 
attached at the 3-position on the pyran, the rest of the sub-classes have the B-
ring attached at the 2-position.  The flavones contain a 2,3-unsaturation in the C-
ring, and the flavonols possess both the 2,3-unsaturation and a hydroxyl group at 
the 3-position.  The flavanones have a saturated 2,3-bond, and the flavanols also 
possess a hydroxyl group at the saturated 3-positions.  The names and 
structures of the flavonoids in the study are listed in Table 2.  
The anti-oxidant activity of these compounds is due to the presence of 
these phenolic hydroxyl groups, which create their electron-donating property 
against free radicals [53].  At the same time, flavonoids are frequently found 
attached to sugars almost exclusively as β-glycosides, where a hydroxyl group at 
positions 3 or 7 is substituted by various glycosides [54, 55].  Glucose is the most 
common residue attached, which ultimately increases the water solubility of 
flavonoids in plants [52, 56].  The deglycosylation of flavonoids may be an 
important first step for their absorption in the body, and this rate is dependant on 
both the structure of the polyphenol and the position or the nature of the attached 
sugars [55].  
Consequently, due to such diversity, flavonoids are able to interact with 
many targets and influence various signaling pathways. This further emphasizes 
the importance of studying their molecular chemistry. 
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Flavonoids in Food 
In the 1930s, scientists Rusznyák and Szent-Györgyi showed that a 
substance from lemon peel reduced capillary permeability and was effective for 
purpura treatment [57].  They named it “Vitamin P,” P for permeability, and later 
reported that it consisted of a mixture of polyphenols.  Flavonoids lost their status 
as vitamins in the 1950s, when it was shown that their removal from the diet did 
not cause any abnormalities.  However, studies since the 1980s have been 
providing strong implications regarding their protective effects against many 
chronic diseases, such as coronary heart disease and cancer.  As the result, the 
World Health Organization (WHO) recommended an intake of about 400 g/day of 
fruits and vegetables, which may save up to 2.7 million lives annually [58]. 
Flavonoids are still considered to be a non-essential dietary components 
found ubiquitously in foods and beverages of plant origin, such as vegetables, 
fruits, teas, wine, and chocolate (Table 4).  Sub-classes of flavonoids, however, 
do not seem to be uniformly distributed in many foods.  For example, grapefruit 
juice has been shown to contain around 200-850 mg/L of total flavonoids, among 
which naringenin is about 145-638 mg/L and the most abundant flavonoid [59].  
Orange juice, however, mainly contains the flavanone hesperidin at about 200-
450 mg/L [60].  Green tea and red wine are rich sources of flavanol catechins, as 
high as 1,000 mg/L, while soy foods are rich source of isoflavones, such as 
genistein and daidzein [61].  
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Table 4.  Sub-classes and common dietary sources of flavonoids. 
Flavonoid sub-class Major Food Sources 
Flavonols Onions, spinach, cherries, apples, broccoli, kale, tomato, berries, almond, tea, red wine 
Flavones Parsley, thyme, celery, peppers, rosemary 
Isoflavones Soybeans, legumes, peanuts, fava beans, red clover 
Flavanols Apples, tea, red wine, chocolate 
Flavanones Oranges, grapes, lemons, psoralea 
Anthocyanidins Berries, grapes, cherries, plums, cashews, hazelnuts, eggplant 
 
 
It has been estimated that the total amount of flavonoid consumed in the 
western diet is about 1 g/day [62], but some studies indicate that this amount can 
vary widely [63].  This may be due to the great diversity of flavonoids and the 
limited data on their content in foods.  Another complication is the fact that the 
flavonoid content is influenced by many other factors, including season, climate, 
sunlight, and food preparation [64].  However, in 2011 the U.S. Department of 
Agriculture (USDA) compiled and published an updated database on the 26 most 
commonly occurring flavonoids in over 500 foods [65].  
Flavonoids as Chemopreventative Agents 
Even though cancer is attributed to genetic mutations, such as the BRCA1 
and BRCA2 genes in breast cancer, known genetic defects only account for up to 
10% of all cases.  On the other hand, lifestyle factors, including diet, smoking, 
and physical activity, account for the majority of cancer cases [66, 67].  A lot of 
the epidemiological data from case-control and cohort studies have found an 
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inverse relationship between the risk of developing certain cancers and the 
consumption of vegetables and fruit [62, 68-70].  The American Institute for 
Cancer Research published a comprehensive report in 2008, which concluded 
that there was convincing evidence for a statistically significant decrease in 
development of certain cancers with consumption of fruits and vegetables [71].  
Additionally, lung, colon, prostate, and breast cancer have been shown to 
be more common in Western rather than in Eastern countries [7].  More 
specifically, it has been reported that China and Japan, where the daily 
consumption of soy products reaches up to 100 mg as opposed to a few 
milligrams in Western countries, have one third the incidence of prostate and 
breast cancer [72].  
Much compelling data highlights the important role of flavonoids as 
chemopreventative agents.  Through extensive studies, flavonoids have been 
shown to possess many biochemical and pharmacological actions that may 
significantly affect cellular systems.  Numerous studies report on the anti-
flammatory, anti-oxidant, antiallergic, hepatoprotective, antithrombotic, antiviral, 
and anticarcinogenic activities of these compounds [73] (Table 5). 
Chemoprevention has been defined as the prevention, inhibition, or 
reversal of carcinogenesis during the progression of cancer, before cellular 
invasion across the basement membrane by pharmacological agents like 
flavonoids [74].  As a result of this slow development and progression, cancer 
has been thought to be a preventable disease.  
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Table 5.  Proposed mechanisms for chemoprevention by phytochemicals. 
Antioxidant activity to reduce the role of ROS and other free radicals 
Inhibition of cell proliferation, oncogene expression, signal transduction pathways, 
inflammation, cell adhesion and invasion, nitrosation and nitration 
Enzyme inhibition: 
   -Phase I enzyme (blocking activation of carcinogens) 
   -Cyclooxygenase-2 
   -Inducible nitric oxide synthase 
   -Xanthine oxidase 
Induction of cell differentiation, cell-cycle arrest, apoptosis, tumor suppressor 
gene expression 
Induction of enzymes and enhancement of detoxification 
   -Phase II enzymes 
   -Glutathione peroxidase 
   -Catalase 
   -Superoxide dismutase 
Enhancement of immune response 
Antiangiogenesis 
Prevention of DNA adduct formation or DNA intercalation 
Regulation of estrogen and steroid hormone metabolism 
Modified from Liu et al. [75]  
 
Furthermore, carcinogenesis is a very complex multistep process that 
includes tumor initiation, promotion, and progression from the initial exposure to 
carcinogen and the ultimate development of cancer [76] (Figure 1).  As 
chemopreventive agents, flavonoids are active at different stages of cancer 
development interfering with the overall process through various mechanisms 
such as modulating mitogenic signaling, survival/apoptotic signaling, cell-cycle 
regulation, angiogenesis, and metastatic effects in the cells [77].  Studies show 
that targets in various signal transduction pathways vary depending on the origin 
of cancer.  For example, flavonoids may inhibit the activity of DNA topoisomerase 
I/II [78], release of cytochrome c from mitochondria and subsequent activation of 
caspases-3, 8 and 9 [79, 80], down-regulation of Bcl-2 and Bcl-xl expression 
 
12 
ii.	  Promotion	  
 
 
 
 
Figure 1.  Model of carcinogenesis and potential consequences of 
flavonoids on cancer progression.  Carcinogenesis is a complex multistep 
process that can be activated by various agents including ROS. Steps:  i. 
Initiation: the exposure or uptake of the carcinogen by a cell and its interaction 
with the DNA.  ii. Promotion: the persistence and replication of the abnormal 
cells, originating preneoplastic cells.  iii. Progression: uncontrollable growth of 
tumors with gradual conversion of premalignant cells to neoplasia with potential 
for metastasis and angiogenesis [9].  Carcinogens are known to affect many 
signaling pathways, such as: modulation of transcription factors (e.g. NF-κB, AP-
1, STAT3), apoptotic proteins (e.g. Akt, Bcl-2, Bcl-XL, caspases, PARP), protein 
kinases (e.g. EGFR, HER2, MAPK), cell cycle protein (e.g. cyclins, cyclin-
dependant kinases), cell adhesion molecules, COX-2, and growth factor 
signaling pathways [7].  Flavonoids may interact with many cellular molecules 
and interfere with the growth and progression of the tumor.  For example, 
kaempherol can stop initiation by inhibiting the metabolic activation of the 
carcinogens by phase I enzymes (CYPs) or their interaction with DNA.  
Naringenin and quercetin, on the other hand, can stimulate detoxification of 
carcinogens by activating phase II enzymes.  Genistein can interfere with 
promotion and progression by inducing cell cycle arrest, apoptosis and/or 
inhibiting metastasis and angiogenesis [81].  
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metabolism 
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• Induce apoptosis 
Initiated 
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  Progression	  i.	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and/or up-regulation of Bax and Bak expression leading to apoptosis [80].  While 
specific molecules have been identified to be involved in the process, the 
induction and regulation still remains unexplained. 
One of the well studied roles of flavonoids is their anti-oxidant potential 
against Reactive Oxygen Species (ROS), which cause DNA damage and 
promote carcinogenesis in biological systems [82].  Since an imbalance between 
production of ROS and the body’s anti-oxidant defenses can cause many chronic 
diseases, the anti-oxidant activity of flavonoids has been regarded as the main 
biological activity for many years.  However, recent bioavailability data has 
challenged this notion.  It has been shown that the concentrations of flavonoids 
are limited due to their low absorption by the body and short half-life in plasma.  
In addition, extensive metabolism by the body significantly alters their redox 
potential.  As a result, their concentrations in the tissue are lower than 
endogenous anti-oxidants, limiting such efficacy in vivo [52, 70].  
Many other studies have, therefore, linked the anti-cancer function of 
flavonoids to modulation of various molecular targets involved in many 
intracellular signaling pathways such as cell signaling, mitogenic signaling, cell 
proliferation, cell cycle regulation, angiogenesis, and metastatic events (Table 6).  
For example, flavonols and flavonones interfere with the activation of 
carcinogens by inhibiting cytochrome P450 enzyme of CYP1A family [69].  Some 
flavonoids also interfere with the activities of many other enzymes such as β-
glucuronidase, lipoxygenase, cyclooxygenase (COX), nitric oxide synthase 
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(NOSs), monooxygenase, thyroid peroxidase (TPO), xanthine oxidase (XOs), 
mitochondrial succinoxidase and NADH-oxidase, phosphodiesterase (PDE), 
phospholipase A2 (PLA2), and protein kinase [83, 84]. 
 
Table 6.  Some of the molecular targets of flavonoids.  
Anti-Apoptotic 
Proteins 
Apoptotic 
Proteins 
Cell-Cycle 
Proteins 
Growth Factor 
Pathways 
Transcription 
Factors 
Protein 
Kinases 
↓Bcl-2 
↓Bcl-XL 
↓Survivin 
↓TRAF1 
↓cFLIP 
↑Caspases 
3, 7, 8, 9 
↑PARP 
↑Bax 
 
↓Cyclin D1, E 
↑p21/WAF 
↑p27Kip/Cip 
↓CDK1,2,4,6,7 
↓TNF 
↓EGF 
↓IFN-γ 
↓IL-1,2,6,8 
↓Erythropoietin 
↓NF-κB 
↓AP-1 
↓STAT1,3,5 
↓β-catenin 
↑p53 
↓IKK 
↓EGFR 
↓HER2 
↓Akt 
↓MAPK 
Modified from Aggarwal et al. [7] 
 
Molecular Targets of Flavonoids 
Flavonoids have been shown to possess many biochemical and 
pharmacological actions that may significantly affect cellular systems by 
modulating various proteins in signaling cascades (Table 6).  While specific 
molecules have been identified to be involved in these processes, the induction 
and regulation of many remain unexplained.  Some of the molecular targets are 
highlighted here.  
Nuclear Factor-κB (NF-κB) is a family of proteins that are pro-inflammatory 
transcription factors that can promote carcinogenesis [85].  Upon activation by 
ROS, cytokines, and other carcinogens, NF-κB is translocated into the nucleus 
and is able to regulate expression of more than 200 genes, which may suppress 
apoptosis and promote proliferation, invasion, metastasis, and inflammation [86].  
Studies have suggested that apigenin, catechin, genistein, quercetin, 
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kaempherol, and luteolin are potent inhibitors of the NF-κB signaling cascade 
through various mechanisms such as inhibition of Bcl-2, Bcl-XL, cyclin D1, matrix 
metalloproteases (MMP), and vascular endothelial growth factor  (VEGF) [7, 87, 
88].  Activation of the serine/threonine protein kinase (Akt) has also been shown 
to support cancer cell survival through activation of NF-κB and inhibition of 
apoptosis [89].  Genistein has been shown to inhibit Akt activation through 
epidermal growth factor (EGF) inhibition [7].  
Activator Protein-1 (AP-1) is also a transcriptional activator that regulates 
expression of several genes involved with apoptosis, cell proliferation, cell 
transformation, inflammation, and innate immune response [90].   For example, 
AP-1 may activate cyclin D1 and repress tumor-suppressor genes such as p53.  
Catechin and quercetin have been reported to suppress the activation of AP-1 
[91, 92]. 
 In addition, defect in the regulation of cell cycle also leads to cancer.  For 
example, overexpression of major cell cycle regulators, such as cyclins and 
cyclin-dependant kinases (Cdk), leads to promotion of carcinogenesis [93].  
Prostate, lung, and breast cancer have been shown to overexpress cyclin D1, 
which is regulated by NF-κB [94-96].  As a result, NF-κB inhibitors such as 
genistein and apigenin are able to induce cell cycle arrest at gap-2 (G2) phase 
and halt the proliferation of cancer cells [7, 97].  
Apoptosis is also an essential part of homeostasis that involves a series of 
events inducing programmed cell death.  Defects in the regulation of apoptosis 
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have also been linked to several factors including NF-κB and AP-1.  Flavonoids 
have been shown to induce apoptosis in some cancer cell lines, while their 
molecular mechanism is not fully understood.  For example, genistein causes 
apoptosis in MDA-MB-468 cells, but not in MCF-7, ZR-75, or MDA-231 cells [98].  
Suggested mechanisms include inhibition of NF-κB and AP-1, DNA 
topoisomerase I/II activity, regulation of heat shock proteins, and release of 
cyctochrome c with activation of caspases-9 and 4 [8, 99].  Catechin, on the 
other hand, causes apoptosis by down regulating the expression of apoptosis 
suppressor proteins, such as Bcl-2 and Bcl-XL [100]. 
 Tumor-suppressor p53 is a transcription factor also involved in many cell 
processes including DNA repair, cell cycle control, and apoptosis.  Upon 
activation, p53 expresses genes that induce apoptosis, cause cell cycle arrest, or 
inhibit angiogenesis [86].  Many flavonoids, therefore, have been shown to 
activate p53 or its target genes.  For example, luteolin induces cell cycle arrest 
and apoptosis by activating p53, p21, and Bax genes [86].  
Finally, many cancers, including liver, breast, lung, and skin, contain 
overexpression of the enzyme cyclooxygenase-2 (COX-2), which leads to 
inflammation [101].  Several transcription factors, such as NF-κB and AP-1, 
cause this overexpression.  Therefore, flavonoids such as luteolin, genistein, 
apigenin, and catechin inhibit these transcriptional factors and suppress COX-2 
transcription. 
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Bioavailability of Flavonoids 
 Bioavailability refers to the amount of any substance that reaches the 
plasma unchanged.  Thus bioavailability of flavonoids determines their activity in 
vivo.  Most of polyphenols are present in the form of esters, glycosides, or 
polymers (called tannins [63]) produced by the plants or as a result of food 
processing, which also increases their water solubility [52, 60].  Therefore, there 
is little chance of absorption by passive diffusion, ATP pumps, or transporters 
when orally administered [52].  In order to be absorbed by the body, they must be 
hydrolyzed or deglycosylated by the intestinal enzymes or the colonic microflora 
[102].  Even though the exact modifications of flavonoids during metabolism are 
not yet fully understood, polyphenols are further broken down and modified by 
methylation, sulphation, and glucuronidation in the liver and/or kidney [103].  This 
is also a common metabolic detoxification process that facilitates biliary and 
urinary elimination of xenobiotics by increasing their hydrophilicity.  It has also 
been reported that for many of the polyphenols the plasma baseline levels are 
reached within 24 hours of consumption [104]. 
Flavonoids undergo extensive phase I deglycosylation and phase II 
metabolism by biotransformation enzymes in the small intestine epithelial cells 
and liver [83, 105].  Three general processes are involved: conjugation with 
thiols, oxidative metabolism, and P450-related metabolism [83].  Extensive 
conjugation of the free hydroxyl groups is thought to be the main reason for low 
oral bioavailability of flavonoids in vivo [106].  As the result, polyphenols are 
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present in low concentrations after consumption and are eliminated shortly 
afterwards.  These metabolic modifications of flavonoids alter the structure and 
ultimately the redox potential of these compounds.  Further studies are needed to 
better understand their bioavailability in vivo. 
Moreover, intestinal absorption of polyphenols has been shown to vary 
greatly.  For example, in vivo studies have reported a 0-60% absorption of the 
original dose with a half-life of 2-28 hours in the body [107].  Many factors such 
as the sugar moiety or gut microflora affect account for these variations.  In 
addition, the amount of flavonoids absorbed in the intestine varies depending on 
the sub-classes.  For example, only 0.2-0.9% of tea catechins are absorbed as 
opposed to 20% for quercetin and isoflavones [69].  Isoflavones appear to have 
the highest bioavailability, while flavonols appear to have the lowest 
bioavailability but the highest half-life in plasma.  Flavanols appear to have the 
shortest half-life [107, 108].  In addition, bioavailability of flavonoids also varies 
based on the source of food consumed.  For example, quercetin absorption from 
onion is four times that of apple or tea [69].  
It is important to note that the most common flavonoids in the diet may not 
be the most active in vivo, and that the metabolites in the plasma may also not 
be the original compound.  As a result, many inconsistencies on the 
bioavailability of flavonoids have been reported.  Compiling comprehensive and 
reliable data in vivo is thus essential, yet has proven to be challenging.  
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Higher Bioavailability and Metabolic Stability of Methylated Flavonoids 
Methylated flavonoids have been studied less extensively due to the 
absence of hydroxyl groups, and because ultimately they lack anti-oxidant 
properties.  However, recent studies have shown that methylated flavonoids were 
metabolically stable and experienced slower hepatic metabolism compare to the 
unmethylated compounds [109].  Studies in rats have shown that methylchrysin 
had a higher oral bioavailability and tissue accumulation, particularly in the liver, 
compared to the unmethylated compound [110].  Methylated compounds have 
also been shown to have a higher rate of intestinal permeability [106].  
Although most of the compounds studied are synthetic, some methylated 
flavonoids have been identified in plants.  For example, methylapigenin is 
present in citrus fruits and methylchrysin is present in fruits and leaves of 
neotropical nutmeg species [110].  Since more in vivo studies relate the 
chemoprevention of flavonoids to the modulation of cellular signaling pathways, 
as opposed to their anti-oxidant effect, greater attention should be given toward 
methylated polyphenols.  
It is important to mention that a different mechanism of action has been 
suggested for the methylated analogues of flavonoids, when comparing their cell 
cycle arrest data.  For example, apigenin have been shown to induce arrest in 
the G2/M phase, while methylapigenin and methylchrysin arrest most cells in the 
G1 phase [110].  Methylated flavones have also been shown to have a higher 
potency, which could be attributed to their higher accumulation in the cell [111]. 
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Consequently, methylation of flavonoids not only increases their oral 
bioavailability, but also their metabolic stability and tissue accumulation.  In 
addition, methylation of the hydroxyl groups has shown to not interfere with the 
anti-proliferative capacity of flavonoids [112].  Taken together, methylated 
flavonoids may prove to be more effective in vivo.  However, more extensive 
studies on their mechanisms of action are still required. 
Structure-Function Relationship of Flavonoids 
 It has been suggested that the structure of flavonoids dictates their 
bioactivity.  In addition, that specific structural features are involved in whether or 
not flavonoids can act as a potent inhibitors of molecular targets such as protein 
kinase C (PKC), tyrosine kinase, and PI 3-kinase [113].  There is still no clear 
consensus on structure-function relationships based on the various structures of 
sub-classes.  While some studies have found no obvious relationship [72, 114], 
others have highlighted important structural features.  For example, the presence 
of 2,3-unsaturation on the C-ring and the number and substitution of hydroxyl 
groups on the A and B-rings have shown to greatly affect the anti-oxidant and 
anti-cancer activity of these compounds [83, 115]. 
One of the important structural features of flavonoids is the presence of 
2,3-unsaturation in the C-ring (Figure 2).  The presence of this double bond has 
shown to enhance the anti-proliferative effect of the flavonoids [83, 112, 115].  In 
addition to the presence of this double bond, number and substitution of hydroxyl 
groups appear to affect the anti-oxidant potential of flavonoids.  For example, 
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three adjacent hydroxyl groups on the A or B-ring (e.g., myricetin with 3’, 4’, 5’-
OH groups) results in a strong anti-proliferative effect [112].  Therefore, it has 
been suggested that more hydroxyl groups lead to better ROS scavenging and 
anti-inflammatory activity [116].  In terms of positions, the hydroxyl group at 4’ in 
the B-ring improves the anti-proliferative effect of the flavonoids, evident when 
comparing apigenin (with 4’-OH group) and chrysin (without 4’-OH) [117]. 
Flavonoids with 5- and 7-OH groups in the A-ring (e.g., apigenin, luteolin, 
quercetin, and kaempherol) significantly inhibit lipogenesis [118].  Kaempherol, 
myricetin, and quercetin (with 3, 5, and 7-OH groups) have been shown to have 
higher anti-oxidant activity [119].  
 
   
Figure 2.  General structure of flavones. 
 
  
Therefore, many researchers have concluded that the presence of a 
particular molecular structure leads to inhibition of several kinases, which 
ultimately induces cell cycle arrest and apoptosis.  It has been suggested that the 
presence of the 4-oxo group, the 2,3-double bond in the C-ring, and the 3’ and 4’-
22 
OH in the B-ring (so-called catechol group) enhances the anti-oxidant and anti-
proliferation activity of flavonoids [53, 73, 112, 116-118, 120]. 
Biphasic Effects of Flavonoids 
Several flavonoids have been shown to have a biphasic effect on 
apoptosis.  For example, apigenin and chrysin were shown to stimulate 
proliferation at low concentrations, while their methylated analogs did not [110].  
The authors concluded that at lower concentrations, apigenin activates ERα-
mediated gene transcription and caused growth stimulation.  At higher 
concentrations, on the other hand, apigenin down regulates protein levels of ERα 
and inhibits protein kinases p38, MAPK, PKA, and Akt, leading to growth 
inhibition [16].  Similarly, genistein has been shown to stimulate growth of ER-
positive cancer cells, such as MCF7, at lower concentrations by acting as an 
estrogen agonist [39].  At higher concentrations, however, genistein inhibits cell 
growth by being an estrogen antagonist and inhibiting tyrosine kinase activity 
[121, 122].  These results highlight the importance of more extensive studies into 
the biphasic effect of some flavonoids, especially in ER-positive cancer cells. 
Flavonoids Used in the Study 
Flavonoids have been shown to modulate many molecular targets 
affecting various cellular pathways within cells.  Some of the specific molecular 
targets of flavonoids used in our study and their effects on various pathways are 
listed in Table 7.  
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Table 7.  Molecular targets of flavonoids used in this study. 
Flavonoid Molecular targets 
Apigenin  ↓ NF-κB, ↑ IκBα 
Catechin ↑ RyR1, ↓ NF-κB 
Chrysin ↓CDK6/cycD, ↓TBK1 
Daidzein  ↓ NF-κB, ↓ STAT-1, ↓ iNOS 
Genistein  ↓ NF-κB, ↓ NF-κB-DNA binding, ↑ IκBα, ↓ IL-8 
Kaempherol  ↓ PGE2, ↓ COX-2, ↓ NF-κB 
Luteolin  ↓ NF-κB, ↓TBK1 
Myricetin  ↓ COX-2, ↓ NF-κB 
Naringenin  ↓ iNOS, ↓ NO, ↓ NF-κB, ↓ STAT-1 
Quercetin  ↓ NF-κB, ↓ AP-1 
Data gathered from [123-127] 
 
Apigenin, chrysin, and luteolin are flavones found in limited quantities in 
leafy vegetables and other herbs.  Apigenin and luteolin have been reported to 
induce cell cycle arrest at G2/M phase.  They also induce apoptosis through 
various pathways including activation of caspases-3, 6, and 9, suppression of Akt 
and NF-κB, and induction of tumor suppressor p53 [41, 128-130].  Chrysin has 
been reported to increase the expression of PPARs, causing cytoplasmic lipid 
accumulation [131].   
Flavonols are the most abundant flavonoid found in leafy vegetables, 
apples, onions, broccoli, and berries.  Kaempherol, myricetin, and quercetin fall 
into this sub-class of flavonoids.  Kaempherol has been shown to induce 
apoptosis through mitochondria-dependent pathways and induce cell cycle arrest 
through down-regulation of serine/threonine protein kinase (PLK-1) [132].  
Kaempherol has also been reported to have a minimal apoptotic effect in MDA-
MB-231 cells, as opposed to MCF-7 cancer cell line [33].  Myricetin has been 
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shown to suppress topoisomerase II [133].  Quercetin is the most ubiquitous 
dietary flavonoid with a daily intake of 25-30 mg in Western countries [66].  
Quercetin has been shown to induce cell cycle arrest at the G1 or G2/M phase, 
depending on the cell lines [40], and cause anti-proliferation by increasing tumor 
suppressor p53, activation of caspases-6, 8, and 9, and suppression of NF-κB, 
COX-2, and Akt [66, 99, 134].  
Naringenin is a flavanone found predominately in citrus fruits and their 
juices.  Naringenin has been shown to impair glucose uptake and inhibit cellular 
proliferation in vitro [129, 135].  It has also been noted that naringenin causes 
apoptosis through a p53-independent induction of caspase-3, activation of 
p38/MAPK, and inactivation of phosphatidylinositol 3-kinase (PI3K) and Akt [123, 
135-137]. 
 Catechin is a flavanol found extensively in tea, apple, grapes, chocolate, 
and red wine.  Many studies have highlighted the chemopreventative potential of 
catechins derived from various green and black teas against several cancers 
including cervical, prostate, and hepatic malignancies [66].  
 Genistein and daidzein are naturally abundant isoflavones found in soy 
products, tea, fruits, and vegetables.  They are commonly known as 
phytoestrogens, with estrogenic activity in the cell [21].  Since approximately 70% 
of all breast cancers express ER [39], ER status is an important factor in 
chemopreventative potential of phytoestrogens and requires careful 
consideration.  It has been reported that some breast cancers are dependent on 
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estrogen for sustained growth, and such phytoestrogens bind to the ER and 
activate it [138].  It has been shown that both isoflavones modulate multiple 
signaling pathways and are able to induce apoptosis via a caspase-3 mediated 
pathway [139].  Daidzein has been shown to disrupt mitochondrial membrane 
potential leading to cytochrome c release and to induce cell cycle arrest at the 
G1 and G2/M phases by up regulating expression of p27 [18, 140].  Therefore, 
daidzein disrupts tumorogenesis through a cell cycle mediated pathway.  
Genistein has been shown to down regulate Bcl-2, up regulate Bax, and inhibit 
proliferation by inducing apoptosis through the MAPK pathway [121, 141]. 
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MATERIALS AND METHODS 
Materials 
Flavonoids and iso-flavonoids were purchased from Indofine or Alexis 
Biochemicals and stocks were prepared at 50 mM in dimethyl sulphoxide 
(DMSO) with the exception of methylluteolin, which was prepared at 25 mM in 
DMSO.  The compounds were used at 25, 50, 100, and 200 µM for all 
experiments.  The maximum DMSO concentration used in experiments was 
0.4% (200 µM flavonoid treatment).  DMSO at this level did not have any effect 
on assays conducted compared to non-DMSO treatment (data not included). 
Propidium iodide was purchased from Sigma.  RNase was purchased from 
Fisher.  Trypan Blue was purchased from Hyclone. 
Cell Culture 
The following human breast cancer cell lines were purchased from the 
American Type Culture Collection (ATCC): BT-474, MCF-7, MDA-MB-231, SK-
BR-3, and ZR-75-1.  BT-474, SK-BR-3, and ZR-75-1 were routinely maintained in 
RPMI 1640 with L-glutamine (HyClone) and supplemented with 10% bovine 
growth serum (BGS) and 1X antibiotic/antimycotic (HyClone) containing 10,000 
units of penicillin, 10,000 µg of streptomycin, and 25 µg of Amphotericin B per 
milliliter.  MDA-MB-231 and MCF-7 cells were maintained in DMEM with high-
glucose, L-glutamine, and sodium pyruvate, supplemented with 10% BGS and 
1X antibiotic/antimycotic.  All cell lines were maintained at 37°C in a humidified 
27 
atmosphere containing 5% CO2  and passaged based on recommended dilutions 
and confluencies from ATCC.  Human Mammary Epithelial Cells (HMEC) were 
purchased from Lonza and were maintained in the recommended media with 
supplements from Lonza. 
Cell Viability Assays 
Cell viability was determined using the CellTiter-Glo® Luminescent Cell 
Viability Assay (CTG, Promega) or Trypan Blue Exclusion Assay (TBE, 
HyClone).  For the CTG assay, 0.5 × 104 cells per well were seeded in 96-well 
white plates (BD Falcon).  After 24h of incubation, media were changed and cells 
were exposed to various concentrations of flavonoids and iso-flavonoids.  The 
CTG assays were initiated at 24, 48, and 72h after exposure to compounds, and 
cells were processed following the manufacturer’s recommend protocol.  Briefly, 
cells were incubated at room temperature on a variable speed shaker for 10 min 
with the CTG reagent, mixed briefly by pipetting, and centrifuged at 300 xg to 
remove bubbles.  Plates were read in a Veritas 96 Well Luminometer (Turner 
Biosystems) or a Glo-Max II Multimode Plate Reader (Promega). 
For the TBE assay, 0.5 x 105 cells per well were seeded in 6-well culture 
dishes.  After 24h of incubation, media were changed, and cells were treated with 
100 µM flavonoid or DMSO as a control.  Cells were harvested by trypsinization 
at 24, 48, and 72h post treatment and resuspended in 1 mL of media.  Cells were 
briefly vortexed, and an equal volume of cell suspension was combined with an 
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equal volume of 0.4% Trypan Blue in PBS.  Cells lacking Trypan Blue were 
counted using a hemocytometer, and the percentage of live cells was calculated. 
Cell Cycle Analysis 
Progression through the cell cycle was analyzed following a previously 
published protocol [142].  Briefly, MDA-MB-231 cells were seeded at 0.5 x 105 
cells per well in 6-well culture dishes.  After 24h of incubation, cells were treated 
with 100 µM of various flavonoids.  Cells were harvested via trypsinization 24 and 
48h after treatment, washed with cold PBS, and processed for cell cycle analysis.  
The cells were fixed in absolute ethanol and stored at −20°C for later analysis.  
The fixed cells were centrifuged at 1000 rpm and washed with cold PBS twice.  
RNase A (20 µg/mL final concentration) and Propidium iodide staining solution 
(50 µg/mL final concentration) was added to the cells.  The cells were incubated 
for 30 min at 37°C in the dark.  The cells were analyzed using a FACSCalibur 
instrument (BD Biosciences) equipped with CellQuest, and 10,000 events were 
collected for analysis. 
Statistical Analysis 
Statistical data were analyzed for the CTG assay using a four-factor 
ANOVA model for drug, cell-line, drug concentration, and time.  F-tests followed 
by Tukey’s multiple comparison adjustment were utilized to identify statistically 
significant differences in cell death.  To compare cell death as measured by CTG 
and TBE, p-values were calculated from two-sided Student t-tests followed by 
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Hochberg multiple comparison adjustments.  Only adjusted p-values of <0.05 
were considered statistically significant. 
For comparison of cell viability to cell cycle arrest, 95% confidence 
intervals were computed for G2 fold change of one (no change) and plotted 
against cell viability as determined by TBE assays.  Dose-response data were 
analyzed using sigmoidal curve fits in Prism (GraphPadSoftware, Inc) with 
variable slope to determine IC50 values.  The top part of the curve was set to 
100% response (0% viability) and the bottom part of the curve to 0% (100% 
viability).  The IC50 values are reported with 95% confidence intervals. 
For comparison between two groups in all other assays, the data were 
analyzed using the two-sided, two independent sample Student t-test with 95% 
confidence intervals reported.  A p-value of <0.05 was regarded as statistically 
significant. 
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RESULTS 
Flavonoid-Induce Cellular Cytotoxicity 
We measured cell viability of five human breast cancer cell lines (Table 1) 
and human mammary epithelial cells (HMEC) after treatment with fourteen 
different flavonoids (Table 2) using two assays.  First, we used Promega’s 
CellTiter-Glo® (CTG) Luminescence assay, which indirectly determines the 
number of viable cells by quantifying the amount of ATP present in a 
metabolically active cell [143].  This assay has been previously used to measure 
amount of cytotoxicity.  The CTG assay utilizes a luciferase reaction producing 
light output to measure the amount of intracellular ATP.  This assay was chosen 
over the conventional MTT or MTS assay because flavonoids have been shown 
to absorb light at the same wavelength as MTT and MTS assays [144, 145], 
which may interfere with the proper interpretation of the data.  Secondly, we used 
a classical trypan blue exclusion (TBE) assay to measure the number of viable 
cells.  After treatment with flavonoids, live cells do not take up trypan blue dye 
because the membrane is intact, and the cells appear clear under the 
microscope. 
Cellular viability was measured at 24, 48, and 72h after treatment with 
flavonoids at four concentrations of 25, 50, 100, and 200 µM (see Appendix B).  
Figures 3 through 6 present the cellular viability measured by the CTG assay 
after 72h of treatment with the four concentrations.  Cellular viability decreased  
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Figure 3.  Analysis of cell viability for five breast cancer cell lines and one 
primary cell line after treatment with 25 µM of flavonoids.  The CTG assay 
was performed 72h after treatment.  The DMSO-treated cell group was set to 
100% cell viability, indicated by a horizontal line.  Flavonoids used in the study 
are indicated along the X-axis.  The Y-axis represents the percent cell viability.  
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Figure 4.  Analysis of cell viability for five breast cancer cell lines and one 
primary cell line after treatment with 50 µM of flavonoids. The CTG assay 
was performed 72h after treatment.  The DMSO-treated cell group was set to 
100% cell viability, indicated by a horizontal line.  Flavonoids used in the study 
are indicated along the X-axis.  The Y-axis represents the percent cell viability.  
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Figure 5.  Analysis of cell viability for five breast cancer cell lines and one 
primary cell line after treatment with 100 µM of flavonoid. The CTG assay 
was performed 72h after treatment.  The DMSO-treated cell group was set to 
100% cell viability, indicated by a horizontal line.  Flavonoids used in the study 
are indicated along the X-axis. The Y-axis represents the percent cell viability.  
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Figure 6.  Analysis of cell viability for five breast cancer cell lines and one 
primary cell line after treatment with 200 µM of flavonoids. The CTG assay 
was performed 72h after treatment.  The DMSO-treated cell group was set to 
100% cell viability, indicated by a horizontal line.  Flavonoids used in the study 
are indicated along the X-axis.  The Y-axis represents the percent cell viability.  
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over time and increasing flavonoid concentration. Data were analyzed for the 
CTG assay using a four-factor ANOVA model for drug, cell line, drug 
concentration, and time.  F-tests followed by Tukey’s multiple comparison 
procedure were used to find statistically significant differences in cell death.  An 
ANOVA table with the prospective p-values for this comparison is presented in 
Appendix A.  There was a significant time-dose effect on cytotoxicity by the 
flavonoids in all cancer cell lines, as well as HMECs, tested.  Maximum cell death 
was measured at 72h after initial treatment (p<0.001).  Surprisingly, the data 
suggested that some flavonoids stimulated cellular proliferation, especially at the 
lower concentrations with data points at a higher than 100% cell viability as 
shown in Figure 3 (also see Appendix B). 
Becaues the CTG assay determines the number of viable cells indirectly, 
by quantifying the amount of ATP, we also conducted the TBE assay in order to 
measure the actual number of viable cells.  By comparing these data with the 
CTG, we were able to identify wether a viability of higher than 100% was due to 
stimulation of the cells or was a result of the increase in the amount of ATP 
produced by the cells.  We chose to measure only cellular viability after 72h of 
treatment with flavonoids since this time point showed the maximum effect, as 
determined in the CTG assays.  These results suggested that the two assays, 
CTG and TBE, did not show the same amount of cellular viability (Figure 7).  The 
majority of the data points lie on the left side of the line indicating a lower TBE 
percentage and higher CTG percentage.  The results appear as a bar graph in  
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Figure 7.  Comparative analysis of cell viability in CTG 
and TBE after 72h of flavonoid treatment at four 
different concentrations.  The key to flavonoids is 
provided on the right.  The X-axis represents percent cell 
viability from TBE.  The Y-axis represents percent cell 
viability from CTG.	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Appendix C.  Apigenin, chrysin, genistein, kaempherol, luteolin, and quercetin 
consistently showed a higher cell viability using the CTG assay than the TBE 
assay for all cell lines tested.  This suggested that these compounds were 
capable of increasing the amount of ATP present in the cells. 
In addition, IC50 curves were calculated for all flavonoids after 72h of 
treatment using the results from the TBE assay.  Table 8 shows the calculated 
IC50s with 95% confidence interval ranges indicated in parenthesis.  Table 9 is a 
summary of the findings regarding cell death in breast cancer cell lines.  
Categories are based on the percent viability by TBE in combination with the 
IC50 data and grouped flavonoids based on how effectively they induced cellular 
cytotoxicity.  Apigenin, m-apigenin, and luteolin were the most effective at 
inducing cytotoxicity in all cell lines tested.  In certain cell lines, quercetin, m-
quercetin, m-luteolin, kaempherol and chrysin were also very effective at 
inducing cytotoxicity but were ineffective in other cell lines.  Genistein, m-
naringenin, and daidzein were very weak inducers of cytotoxicity in all breast 
cancer cell lines.  Finally, myricetin, naringenin, and catechin were unable to 
induce cytotoxicity in any of the breast cancer cell lines tested.  These results 
indicated that not all flavonoids were capable of inducing cytotoxicity in breast 
cancer cell lines. 
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Table 8. IC50 data for flavonoid-induced cell death after 72h.  Values are 
reported in µM.  Values in the parenthesis are the range for the 95% confidence 
interval.  A value of >200 µM indicates that flavonoid did not induce cellular 
death.  M-apigenin represents methylapigenin. 	  
 BT-474 MCF-7 MDA-MB-231 SK-BR-3 ZR-75-1 
Apigenin 49 (43-56) 
2 
(0.33-16) 
14 
(11-19) 
32 
(23-46) 
14 
(43-48) 
M-apigenin 42 (35-52) 
40 
(17-94) 
33 
(27-40) 
53 
(36-77) 
38 
(18-62) 
Catechin >200 >200 >200 >200 >200 
Chrysin 80 (66-95) 
34 
(28-40) 
40 
(35-45) 
34 
(27-42) 
59 
(48-72) 
Daidzein 154 (129-182) 
102 
(80-130) 
179 
(144-222) 
97 
(69-139) >200 
Genistein 97 (61-154) 
74 
(52-105) 
51 
(43-61) 
30 
(18-53) 
81 
(68-96) 
Kaempherol 77 (62-96) 
25 
(16-40) 
38 
(31-47) 
48 
(40-58) 
80 
(61-106) 
Luteolin 13 (6-27) 
5 
(14-20) 
16 
(14-20) 
13 
(9-20) 
32 
(28-37) 
M-luteolin >200 >200 21 (12-38) 
133 
(87-200) 
150 
(100-225) 
Myricetin >200 >200 >200 >200 160 (77-330) 
Naringenin >200 >200 >200 >200 >200 
M-naringenin 69 (58-82) 
102 
(64-161) 
75 
(59-96) 
72 
(54-96) 
40 
(22-74) 
Quercetin >200 102 (62-161) 
101 
(82-124) 
64 
(55-75) 
47 
(29-77) 
M-quercetin >200 105 (64-171) 
54 
(39-75) 
78 
(50-123) >200 
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Table 9.  Summary of findings for cell death using the TBE assay and IC50 
values.  Categories were created based on strong killing (>80% and IC50<50 
µM), weak killing (20-70% and IC50<100 µM), or no killing (<20%). 
Kills Strongly (>80%) Kills Weakly Does Not Kill 
Non-Selective Selective (20-70%) (>20%) 
Apigenin 
Methylapigenin 
Luteolin 
Chrysin 
Genistein 
Kaempherol 
Methylluteolin 
Quercetin 
Methylquercetin 
Daidzein 
Methylnaringenin 
Naringenin 
Catechin 
Myricetin 
 
Cell Cycle Arrest does not Correlate with Cell Death 
The ability of flavonoids to induce cell cycle arrest was assessed by flow 
cytometry, and the data were compared to cellular viability by the TBE assay.  All 
breast cancer cell lines were treated with 100 µM flavonoid and processed at 24 
and 48h post-treatment.  Figure 8 represents fold change in G2/M DNA content 
of flavonoid-treated cells from DMSO-treated control compared to the cell viability 
data calculated by the TBE assay.  Points to the right of the confidence intervals 
indicate a significant increase in DNA content due to an arrest in the G2/M 
phase.  Points to the left of the confidence intervals indicate a decrease in DNA 
content due to an arrest in the G1 phase.  Table 10 summarizes the cell cycle 
arrest findings.  Besides catechin, all the flavonoids arrested the cell cycle of the 
different breast cancer cell lines either at the G1 phase or the G2/M phase, and 
the arrests were statistically significant (p<0.05). 
The majority of flavonoid-induced cell cycle arrest was in the G2/M phase 
with the exception of m-quercetin and m-naringenin, which consistently arrested
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Figure 8.  Cell cycle arrest does not correlate with cell 
viability. We measured cell cycle arrest at 24 and 48h 
treatment with 100 µM flavonoids and plotted the results against 
cellular viability as measured by TBE assay.  The X-axis has the 
fold G2/M DNA content change compared to DMSO-treated 
control.  The Y-axis represents the cell viability from the TBE 
assay.  The key to the flavonoids is provided on the right.  
Vertical bars indicate the 95% confidence interval for no 
significant change in G2/M DNA content in treated cells. 
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cell lines in G1 phase.  It has been previously shown that methylated versions of 
various flavonoids arrest cells in the G1 phase [110], and our data supported 
these findings.  
It is noteworthy that cell cycle arrest did not occur in all cell lines for a 
particular flavonoid (Table 10).  For example, apigenin and chrysin arrested all 
breast cancer cell lines in G2/M phase with the exception of SK-BR-3 cells.  
Another group reported that apigenin is able to induce cell cycle arrest in SK-BR-
3 cells [41] .  We were unable to reproduce this result. However, apigenin does 
induce cytotoxicity in SK-BR-3 cells and is similar to what was reported by this 
group.  Therefore, it remains inconclusive whether or not cell cycle arrest occurs 
upon apigenin treatment in SK-BR-3 cells. 
Kaempherol and quercetin were the only two flavonoids that consistently 
arrested all cell lines tested at both 24 and 48h.  Kaempherol is also a very 
strong inducer of cellular cytotoxicity in all cell lines, whereas quercetin is more 
selective in its cytotoxicity.  Naringenin, daidzein, m-luteolin, and myricetin are all 
compounds that were not able to induce cellular cytotoxicity at very high levels.  
All of these compounds were able to induce cell cycle arrest in some cell lines, 
but not others.  Taken together, these results suggest that cell cycle arrest may 
not be a strong indicator of whether or not a flavonoid is able to induce cellular 
cytotoxicity.  From these data, we can conclude that flavonoids are able to exert 
their effects regardless of cell line used. 
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Table 10.  Summary of cell cycle arrest identified in all breast cancer cell 
lines after 24 and 48h with 100 µM flavonoid treatment.  NE indicates that 
there was no cell cycle arrest detected that was statistically significant.  G2 
corresponds to arrest during the G2/M phase, G1 corresponds to arrest during 
the G1 phase, and when indicated was statically significant (p<0.05).  Results 
shown represent the averages of at least three independent experiments. 
 
 
BT-474 MCF-7 MDA-MB-231 SK-BR-3 ZR-75-1 
24 48 24 48 24 48 24 48 24 48 
Apigenin G2 G2 G2 G2 G2 G2 NE NE G2 G2 
M-apigenin G2 NE G2 NE G2 G2 NE G2 G2 G2 
Catechin NE NE G2 NE NE NE NE NE NE NE 
Chrysin G2 G2 G2 G2 G2 G2 NE NE G2 G2 
Daidzein NE NE G2 NE NE NE NE G1 NE NE 
Genistein G2 G2 G2 NE G2 G2 G2 G2 G2 G2 
Kaempherol G2 G2 G2 G2 G2 G2 G2 G2 G2 G2 
Luteolin G2 G2 G2 G2 G2 G2 NE G1 G2 G2 
M-luteolin G2 G1 NE G1 NE NE G1 G1 NE G1 
Myricetin NE NE NE G1 G2 NE G2 G2 G2 G2 
Naringenin G2 G2 G2 NE G2 G2 NE NE NE NE 
M-naringenin NE NE NE G1 G1 NE G1 G1 NE G1 
Quercetin G2 G2 G2 G2 G2 G2 G2 GE G2 G2 
M-quercetin NE G1 G1 G1 G1 G1 G1 G1 NE G1 
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DISCUSSION 
Flavonoid-Induce Cytotoxicity and Apoptosis Appear to be Independent of 
a Particular Signaling Pathway 	  
We undertook a comprehensive study evaluating flavonoid-induced 
cellular cytotoxicity.  We used a variety of breast cancer cell lines and flavonoids 
to characterize this cellular cytotoxicity.  We chose the cell lines based on their 
lack of expression in various signaling pathways (Table 1).  Some of these same 
cell lines have been used in previous studies, listed in Table 3, to characterize 
the effect of flavonoids on cellular proliferation and cytotoxicity.  We chose 
flavonoids from various sub-classes (Table 2) in order to determine if there was a 
structural-functional relationship within the chemical structures for induction of 
cytotoxicity.  
Apigenin, m-apigenin, and luteolin induced the strongest cytotoxicity in all 
breast cancer cell lines tested.  Becasue these compounds induced cytotoxicity 
equally well on all cell lines, we concluded that the mechanism of action was 
independent of a particular signaling pathway component, such as HER2, p53, 
and EGFR.  
The isoflavonoids are considered to be phytoestrogens because of their 
structural similarity to the mammalian steroid hormone 17β-estradiol.  Both have 
been reported to bind to the estrogen receptor and activate it [138].  Some breast 
cancers have been shown to be dependent on the estrogen receptor for 
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sustained growth.  Therefore, circulating phytoestrogens could be harmful by 
stimulating growth of breast cancer.  Interestingly, consumption of foods rich in 
phytoestrogens correlates with reduced risk in breast cancer [148].  Our studies 
indicate that daidzein is a weak inducer of cellular cytotoxicity regardless of the 
cell line tested.  However, genistein appears to be selective for ER-negative cell 
lines in the ability to induce cytotoxicity. 
We have shown that the same flavonoids, which induce cytotoxicity in 
breast cancer cells, are able to induce cytotoxicity in HMECs.  This is in contrast 
to previous reports in the literature, which have indicated that genistein is unable 
to decrease cell viability in MCF10A cells (Table 3).  However, it should be noted 
that all studies we have seen in the literature generally have not done a 
comparison of HMECs and MCF10A cells.  Our results suggest that flavonoid 
action is through a generalized mechanism and that flavonoids may not directly 
target cancer cells as previously suggested, although this still remains 
controversial.  
We also see cellular cytotoxicity occurring with the methylated derivatives 
of some of the flavonoids.  Of the methylated flavonoids, methylapigenin was 
able to induce cytotoxicity at the equivalent level of apigenin, whereas 
methylluteolin and methylquercetin were not.  Previous studies have shown that 
the methylated versions of various flavonoids tend to be more potent than their 
unmethylated counterparts [106]. 
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By comparing CTG and TBE data, we were also able to show that some 
flavonoids increase the amount of ATP within the cell.  It is important to consider 
that CTG determines number of viable cells according to the amount of ATP in 
the cell suspension, and may result in an overestimation of cell viability for these 
flavonoids.  It has also been reported that MTT and MTS-based methods result in 
an underestimation of cytotoxicity due to reduction of MTT and MTS by some 
flavonoids and formation of formazan [144].  These results further demonstrate 
the need for a careful consideration of the methods utilized for evaluating cellular 
proliferation of flavonoids. 
Our studies indicate that flavonoid induction of cellular cytotoxicity may be 
occurring through a non-classical apoptotic mechanism.  We have previously 
reported that flavonoids are able to inhibit caspase-3 and caspase-7 at similar 
concentrations that induce cytotoxicity in our breast cancer cell lines [149].  We 
also showed that flavonoids are cytotoxic to cells, which lack caspase-3 and 
caspase-7.  Taken together, these results do not suggest a particular signaling 
pathway required for the chemopreventative property of flavonoids.  Instead, the 
data may suggest that the classical apoptosis may not be the primary form of 
cellular cytotoxicity and that the importance of individual signaling component 
modulating cell growth may be cancer cell type specific.  However, more 
extensive research into the role of flavonoids in each signaling pathway is still 
required.  
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Structure-Function Relationship of Flavonoid Effects 
We suggest that flavonoids that are able to induce cytotoxicity may do so 
in a generalized cellular mechanism.  We have been able to identify structural 
features, which we believe is important in flavonoid-induced cytotoxicity.  Our 
data suggested that the flavones and some flavonols were most cytotoxic, while 
the flavanones tested were far less effective at killing cancer cells.  This further 
suggests that the planarity of the benzopyran nucleus may be a key structural 
element in cytotoxicity.  For example, we noted that both naringenin and (+)-
catechin were identical to apigenin and quercetin, respectively, with the 
exception of the 2,3-double bond on the C-ring.  However, both naringenin and 
(+)-catechin did not induce cytotoxicity in cell lines tested.  Isoflavonoids were 
weaker in their ability to induce cytotoxicity.  These observations suggest that 
flavonoid cytotoxicity requires the compounds to be planar in nature, possess the 
2,3-double bond on the C-ring and the B-ring to be attached at the 2-position of 
the benzopyran core.  We also believe that the planarity of the flavonoid(s) may 
be important in their ability to cross the cell membrane and enter the cytosol and 
that the B-ring’s position is important for binding to a protein target.   
Future Perspective 
Significant progress has been made during the past thirty years on not 
only efficacy, but also identifying many molecular mechanisms altered by 
flavonoids in various cancers.  Medicinal plants have played pivotal roles in the 
development of new drugs to treat human diseases.  Some of the earliest forms 
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of chemotherapy originate from natural products derived from both plants and 
marine organisms.  It is no surprise to see resurgence in the investigation of 
natural products for their anti-cancer use.  Flavonoids have been shown to be 
potent bioactive molecules that possess anticarcinogenic effects.  Flavonoids 
have also emerged as potential chemopreventative candidates for cancer.  
Despite this promise, contradictory results regarding molecular mechanisms of 
action have been reported from many laboratories.  Although results from in vitro 
experiments are not always predictive of medicinal utility, they constitute a 
valuable tool for studying the effects of the drug candidate on molecular targets 
involved in tumor growth and survival.  In addition, much attention has been 
given to the gene targets altered by these chemopreventative agents.  
Many other techniques, especially cDNA microarray, may provide great 
insight into such gene-drug relationship.  cDNA microarray enables researchers 
to identify many of altered gene expression as result of treating cells with 
flavonoids.  This will provide bases for analysis of the functional groups and 
molecules involved in many process such as tumor growth and progression, cell 
cycle, apoptosis, DNA damage, inflammation and even metabolic alterations/ 
activations.  It is also noteworthy that many researchers study the protective 
mechanism of such compounds.  Since these dietary compounds are not 
classified as drugs, flavonoids do not require FDA approval to be available for 
consumption [150].  Therefore, a thorough evaluation of their toxicity and drug 
interactions is necessary to ensure their safety for the public. 
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More extensive studies are also needed on absorption and bioavailability 
of flavonoids in the body.  In addition, the majority of dietary compounds contain 
a mixture flavonoids and other polyphenols.  It has been shown that some 
flavonoids may have synergistic effects, whereas individually they are not 
effective chemopreventative agents [151].  This is more relevant as bioavailability 
data limit the concentration of flavonoids in vivo.  Therefore, further extensive 
studies are necessary. 
Consequently, more studies are clearly needed to resolve the conflicting 
data, to more fully understand the mechanism(s) of anti-cancer activity of 
flavonoids, and to evaluate their potential as therapeutic agents.  As proteins that 
interact with flavonoids are identified, these discoveries will provide the basis for 
rational drug design. 
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APPENDICES 
Appendix A.  Modified 4-Way ANOVA Table for the CTG Cell Viability Data. 	  	  
Source p-value 
Drug < 1E-300 
Dose < 1E-300 
Time < 1E-300 
Cell Line 2.417E-261 
Drug*Dose < 1E-300 
Drug*Time 3.187E-209 
Drug*Cell Line < 1E-300 
Dose*Time 1.1998E-80 
Dose*Cell Line 9.1602E-76 
Time*Cell Line 2.0637E-49 
Drug*Dose*Time 4.7378E-32 
Drug*Dose*Cell Line < 1E-300 
Drug*Time*Cell Line 8.5134E-77 
Dose*Time*Cell Line 1.9173E-07 
Drug*Dose*Time*Cell Line 2.694E-06 
R2= 0.758 	  
Table 11.  Data analysis was conducted for the CTG assay using a four-
factor ANOVA model for drug, dose, time, and cell line.  F-tests followed by 
Tukey’s multiple comparison adjustment were utilized to identify statistically 
significant differences in cell death. 
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Measured by CTG Assay. 
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Figure 9.  The CTG assay was performed after cells were treated with each 
flavonoids.  The DMSO-treated cell group was set to 100% cell viability, which is 
indicated by a horizontal line.  Figures 9A-9L represent the CTG data for 
concentrations of 25, 50, 100, 200 µM after 24, 48, 72h treatments.  The key to 
cell lines tested is provided on the right.  Flavonoids used in the study are 
indicated along the X-axis.  The Y-axis represents the percent cell viability. 
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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100 µM Treatment After 24h  
 
 
Pe
rc
en
t C
el
l V
ia
bi
lit
y 
Flavonoids  
 
72 
Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
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Appendix B.  Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment 
Via CTG Assay.   
9L 
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Appendix C.  Comparinson of CTG and TBE Assays for 
Measuring Cell Viability with 100 µM Flavonoid for 72h. 	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Figure 10.  Bar graphs comparing cell viability between CTG and TBE 
assays were created for the cells treated with 100 µM after 72h, and 
standard deviations are indicated.  Results shown are for all flavonoid 
treatments in SK-BR-3 and ZR-75-1 (A), and BT-474, MCF7, and MDA-MB-231 
(B).  
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Appendix C.  Comparison of CTG and TBE Assays for 
Measuring Cell Viability with 100 µM Flavonoid for 72h. 
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Appendix D.  Summary of Significant Differences Between Data for CTG and 
TBE Assays. 	  
 BT-474 MCF-7 MDA-MB-231 SK-BR-3 Zr-75-1 
Apigenin 200,100,50,25 200,100,50,25 50,25 200,100,50,25 25 
M-apigenin 25 100,25 25 200 200,100,25 
Catechin 200 ND ND ND 25 
Chrysin 25 200,100,50,25 100,50,25 100,50,25 200,50,25 
Daidzein 200,100,50 200,100,50 200,100,50 50 ND 
Genistein 50 50 200,100,50 200,100,50,25 ND 
Kaempherol 200,50,25 200,50,25 200,100,50,25 200,100,50,25 200,100,50,25 
Luteolin 100,50,25 200,100,15 200,50,25 200,50,25 200,100 
M-luteolin ND 25 200,100,50,25 100,50 200,100 
Myricetin 200 50,25 25 200 ND 
Naringenin ND 50 200,50,25 200,100,50 200,100,50,25 
M-naringenin ND 50 ND 200 200,100,50,25 
Quercetin 100,50,25 50 200,100,50,25 200,100,50 ND 
M-quercetin ND 200,50 25 100 200,100 	  
Table 12.  Summary of statistical significant differences (p-values <0.05) 
noted between CTG and TBE assays.  Results shown are after Hochberg 
multiple comparison adjustment.  ND corresponds to no significant difference. 
